Boston-based Beth Israel Deaconess Medical Center researchers have found GLP-1 drugs were associated with fewer peptic ulcer diagnoses among patients with Type 2 diabetes.
The study, published in Clinical Gastroenterology and Hepatology, analyzed EHR data from more than 66,000 adults enrolled in the National Institutes of Health’s All of Us Research Program, according to an April 29 hospital news release. Patients using GLP-1 medications had 44% lower odds of being diagnosed with peptic ulcer disease compared to nonusers.
In a subgroup analysis, patients who stopped taking metformin and initiated a GLP-1 drug had a 56% lower risk of developing peptic ulcer disease than those who switched to insulin.
Peptic ulcer disease affects an estimated 4 million people each year and remains a cause of hospitalization, particularly among patients with Type 2 diabetes. Researchers said the findings suggest GLP-1 receptor agonists may have broader gastrointestinal effects, including anti-inflammatory properties and potential roles in mucosal protection.
The post Boston hospital links GLP-1 use to fewer ulcers appeared first on Becker's Hospital Review | Healthcare News & Analysis.
